Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intra-Cellular Therapies, Inc. (ITCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INTRA-CELLULAR THERAPIES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND RAISES 2023 CAPLYTA SALES GUIDANCE"
07/17/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/28/2023 8-K Quarterly results
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Quarterly results
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.8% stake in Intra-Cellular Therapies Inc.
02/09/2023 SC 13G/A FMR LLC reports a 12.7% stake in INTRA-CELLULAR THERAPIES INC
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 SC 13G/A WASATCH ADVISORS INC reports a 5% stake in Intra-Cellular Therapies, Inc.
01/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
12/22/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® for Specific Patient Populations"
04/21/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors NEW YORK, April 21, 2022 — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. “We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Rene's extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innovative treatments to improve the lives of patients.” Abo..."
03/01/2022 8-K Quarterly results
03/01/2022 10-K Annual Report for the period ended December 31, 2021
02/10/2022 SC 13G/A WASATCH ADVISORS INC reports a 10.1% stake in Intra-Cellular Therapies, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy